<DOC>
	<DOC>NCT02406989</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of MS-553 in healthy volunteers. Endpoints are safety, tolerability, and pharmacokinetics. Subjects are dosed for 14 days.</brief_summary>
	<brief_title>A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>In good general health with BMI 18 to 32 kg/m2. Females must be nonpregnant, nonlactating, postmenopausal at least 2 years or surgically sterilized at least 6 months prior History of skin rash, migraine, or clinically significant ocular diseases, conditions predisposing to QT prolongation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>